Skip to content
PeptideGuideA closer look at the research
← All peptide reviews

Tissue repair research

TB-500 Research review

Why a trial of thymosin beta-4 eye drops cannot validate injectable TB-500 recovery claims.

01 / Context first

The research setting

Adults with dry eye received a thymosin beta-4 ophthalmic formulation, not injectable TB-500.

02 / The findings

What the sources found

  • The selected trial missed its primary endpoints; some secondary outcomes improved.

03 / The open questions

Where the evidence stops

  • The tested formulation, route, and condition differ from TB-500 injury-recovery claims.
  • FDA identifies TB-500 as a thymosin beta-4 fragment; it should not be treated as interchangeable with the trial product.

04 / Safety context

Before drawing conclusions

FDA describes immune-response and impurity concerns and missing human exposure information for the TB-500 fragment.

These reviews do not provide instructions for self-treatment. Discuss personal medical questions with a qualified clinician.

05 / Go to the originals

Read the sources

Inspect the original research and regulatory context behind this review.

  1. Original research — PubMed abstractThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. ↗
  2. FDA safety informationCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗

Sources checked September 12, 2026. Next editorial review due December 11, 2026.

Read the review methodology →